Immunovaccine to Present at Three Conferences in June
(firmenpresse) - HALIFAX, NOVA SCOTIA -- (Marketwire) -- 06/13/12 -- Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX VENTURE: IMV), a clinical stage vaccine company, today announced that John Trizzino, Chief Executive Officer, and Marc Mansour, Ph.D., Chief Science Officer, will participate in three upcoming conferences during the month of June. Details regarding these events are as follows:
2012 BIO International Convention
The Biotechnology Industry Organization (BIO) International Convention will take place June 18-21, 2012 at the Boston Convention and Exhibition Center in Boston.
Bloom Burton & Co. Healthcare Investor Conference
The inaugural Bloom Burton & Co. Healthcare Investor Conference will take place June 21, 2012 at the Toronto Board of Trade in Toronto.
Cancer Vaccines & Active Immunotherapeutics
The Cancer Vaccines & Active Immunotherapeutics 3rd Annual Summit will take place June 26-28, 2012 at the Sheraton Boston Hotel in Boston.
About Immunovaccine
Immunovaccine Inc. applies its novel vaccine delivery platform to the development of vaccines for cancer therapy and infectious diseases. The company's DepoVax™ platform is a patented lipid delivery system that presents antigens plus adjuvant to the immune system for a prolonged period and has the potential to enhance immune responses. Immunovaccine has advanced its platform technology and proprietary cancer vaccine into Phase I human clinical trials and has demonstrated both safety and immunogenicity potential. The Company is also capitalizing on the broad potential of its delivery platform by creating new DepoVax-based vaccines through multiple development collaborations. In addition to the Company's human health vaccine strategy, it continues to capture value from animal health vaccine applications. Immunovaccine has several key partnerships in the animal health sector including an agreement with Pfizer Animal Health, which has licensed the Company's delivery technology platform to develop vaccines for livestock. Connect at .
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Immunovaccine Inc.
Kimberly Stephens
(902) 492-1819
Vida Communication - Media
Tim Brons
(415) 675-7402
Vida Communication - Investors - US
Stephanie Diaz
(415) 675-7401
Capital Ideas Investor Relations - Investors - Canada
Nadine Desruisseaux
(647) 202-5292
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 13.06.2012 - 06:05 Uhr
Sprache: Deutsch
News-ID 1123893
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
HALIFAX, NOVA SCOTIA
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 130 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Immunovaccine to Present at Three Conferences in June
"
steht unter der journalistisch-redaktionellen Verantwortung von
Immunovaccine Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
